<DOC>
	<DOC>NCT00683358</DOC>
	<brief_summary>Feasibility and efficacy of combined modality intervention using chemotherapeutic agent gemcitabine with anti-angiogenic peptide vaccination targeting VRGFR1 should be determined in case of advanced/inoperable or therapy-resistant pancreatic cancer patients. Gemcitabine 1,000mg/m2 BSA will be administered on day1, day8, day15, day29, day36, day43, respectively. HLA-A*2402-restricted VEGFR1-derived peptide (VEGFR1-A24-1084; SYGVLLWEI) emulsified with Montanide ISA51 will be subcutaneously injected twice weekly for 8weeks (total 16 doses).</brief_summary>
	<brief_title>Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer</brief_title>
	<detailed_description>HLA-A*2402-restricted cytotoxic T lymphocyte (CTL) clones were obtained from healthy volunteer donor peripheral blood. These CTL clones showed potent cytotoxicities selectively against VEGFR1-expressing target cells in HLA-class I-restricted manner.</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Heterozygote or homozygote of HLAA*2402 allele Inoperable or recurrent pancreatic cancer with or without any prior therapy Difficult to continue the prior therapy due to treatmentrelated toxicities ECOG performance status 02 Evaluable primary or metastatic lesion with RECIST criteria Clearance period from prior therapy more than 4 weeks Life expectancy more than 3 months Laboratory values as follows 2,000/μL&lt;WBC&lt;15,000/μL Platelet count&gt;100,000/μL AST&lt;150IU/L ALT&lt;150IU/L Total bilirubin&lt;3.0mg/dl Serum creatinine&lt;3.0mg/dl Pregnancy (refusal or inability to use effective contraceptives) Breastfeeding Active or uncontrolled infection Systemic use of corticosteroids or immunosuppressants Uncontrollable brain metastasis and/or meningeal infiltration Unhealed external wound Possibilities of complicated paralytic ileus or interstitial pneumonitis Decision of not eligible determined by principal investigator or attending doctor</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>cancer</keyword>
	<keyword>pancreas</keyword>
	<keyword>advanced</keyword>
	<keyword>peptide</keyword>
	<keyword>vaccination</keyword>
	<keyword>VEGFR1</keyword>
	<keyword>HLA</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>IFA</keyword>
	<keyword>Cancer of Pancreas</keyword>
	<keyword>Neoplasms, Pancreatic</keyword>
	<keyword>Pancreas Cancer</keyword>
</DOC>